Cabot China & Emerging Markets Report applies the time-tested Cabot system to the fastest growing stocks in the world.
If you're considering emerging market stocks then you'll want to see what Chief Analyst Paul Goodwin has to share. By combining expert stock selection and award-winning market timing you'll find this advisory easy to follow.
Invest in the advisory that has been recognized as a top performer by Hulbert, MarketWatch, SIIA, and more under Paul Goodwin.
China & Emerging Markets Report features one stock every two weeks. The advisory presents a model portfolio, which is fully invested with 10 positions. The portfolio uses the Cabot Emerging Markets Timer to guide its cash position and weightings in individual stocks. All recommendations are followed up weekly with buy, hold and eventually sell ratings. The performance shown is the gain in Cabot China & Emerging Markets Report stocks since 12/31/15 compared to the S&P 500 over the same time period, not including dividends, as of 6/29/15.
150% in VipShop Holdings
87% in Baidu
93% in BitAuto
111% in Qihoo 360
Cabot China & Emerging Markets Report will show you how to profit from the fastest-growing stocks in the world.
Try Cabot China & Emerging Markets Report for 60 days. If you don’t like it, you don’t pay.
What our Customers say about China & Emerging Markets Report
Cabot China & Emerging Markets Report is notable for the portfolio discipline it applies to this most volatile market.
Peter Brimelow, MarketWatch
Paul, I am very happy to stay in cash and stick with you. I subscribe to several other newsletters, one of which lost 50%. I didn't lose 50% because I set stops but the newsletter didn't recommend stops and still has buys on everything.
K. Shick, Hoschton, Georgia, U.S.A.
Over the past five years, the letter is up 18.76% annualized against 1.11% annualized for the total return Wilshire 5000. This is unquestionably one of the most remarkable records we’ve seen in 30 years of Hulbert Financial Digest monitoring.
Peter Brimelow, MarketWatch 10/27/10
Are you ready to get started with your risk-free trial subscription?